INTRODUCTION {#sec0005}
============

Myasthenia gravis (MG) is an autoimmune disease characterized by heterogenous patterns of muscle weakness. Earlier observational studies have suggested that ocular, bulbar or generalized weakness respond differently to different therapies \[[@ref001]\]. For example, both Barnett et al. and Bhanushali et al. found that ocular symptoms respond relatively well to prednisone treatment. Therefore, an outcome measure's lack of sensitivity for weakness in either of these domains might result in failure to observe significant treatment effects. In an earlier study, we found that Myasthenia Gravis Activities of Daily Living (MG-ADL) had a lower sensitivity for changes in generalized weakness \[[@ref005]\]. In addition, a prior study reported that patients considered limb weakness as most the disabling symptom, further stressing the importance of a high sensitivity for generalized weakness \[[@ref006]\]. The recently developed Myasthenia Gravis Impairment Index (MGII) is a promising measure as it has less floor effects and a higher relative efficiency in its responsiveness to treatment effect compared to other MG measures \[[@ref007]\]. The MGII has 22 patient reported and 6 examination items, with 10 items reflecting generalized weakness (appendix). This study aimed at validating the MGII in a Dutch cohort of MG patients and analyzing the sensitivity of the MGII for changes in generalized weakness.

METHODS {#sec0010}
=======

Patients {#sec0015}
--------

We included a prospective cohort of MG patients under treatment at Leiden University Medical Center (LUMC) between 2016 and 2017. The MGII, Quantitative Myasthenia Gravis (QMG), MG-ADL, EQ-5D visual analog (EQ VAS), Myasthenia Gravis Composite (MGC) and ACTIVLIM (acronym of "ACTIVity LIMitations"; an ADL-scale focusing on generalized weakness) scores were recorded in all MG patients who visited the outpatient clinic as part of routine clinical care. The diagnosis of MG was based on a combination of clinically confirmed fluctuating muscle weakness and the presence of serum autoantibodies to the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). Seronegative myasthenia gravis (SNMG) was defined as fatigable muscle weakness in combination with abnormal decrement (at least 10%) during low-frequency repetitive nerve stimulation, increased jitter in single-fiber EMG testing or a positive neostigmine test \[[@ref009]\]. This study was approved by the Medical Ethics Boards of the Leiden University Medical Center. All patients provided informed, written consent prior to study participation.

Cross-cultural translation MGII {#sec0020}
-------------------------------

In order to translate the MGII from English to Dutch whilst taking into account cultural differences, we used the back-translation method. The original English version of the MGII was translated to Dutch by a physician at our center. This Dutch version of the MGII was subsequently back-translated to English by independent translators, blinded to the original measure. The back-translation was then compared to the original, and items with major differences were revised \[[@ref010]\].

Subdomains outcome variables {#sec0025}
----------------------------

The first 5 items of the QMG constitute the oculobulbar domain (QMG*ob*) and the remaining 8 items constitute the generalized domain (QMG*gen*). We considered QMG*gen* to be representative of objective generalized muscle weakness \[[@ref005]\]. The first 3 and last 2 items of the MG-ADL constitute the oculobulbar domain (MG-ADL*ob*) and the 4th until the 6th items constitute the generalized domain (MG-ADL*gen*). The first 15 items of the questionnaire and the first 3 physical examination items of MGII constitute the oculobulbar domain (MGII*ob*) and the last 7 items of the questionnaire and the last 3 physical examination items constitute the generalized domain (MGII*gen*).

Statistical analysis {#sec0030}
--------------------

To reproduce earlier reported construct validity findings of the MGII, we analyzed correlations between MGII and other outcome measures \[[@ref008]\]. We investigated whether there were significantly higher generalized scores (MGII*gen,* MG-ADL*gen* and QMG*gen*) in patients with generalized MG compared to ocular MG patients with an unpaired *t*-test. We used a generalized linear model to assess whether MGII*gen* had an additional sensitivity on top of MG-ADL*gen* for changes (*Δ*) in QMG*gen* in individual patients. Results are expressed as B coefficients with 95% confidence intervals (CI), which reflect the additional value of MGII in the prediction of QMG*gen* compared to MG-ADL*gen* alone. The regression line shows the degree in which MGII*gen* can compensate for the mismatch between observed and predicted QMG*gen*. *P*-values \< 0.05 were considered significant. Statistical analyses were performed using SPSS version 23 (IBM Corp., Armonk, NY).

RESULTS {#sec0035}
=======

We included 99 consecutive patients with MG. Of this group, 10 patients had a second visit with all assessments. Demographic and clinical baseline characteristics of all patients are shown in [Table 1](#jnd-7-jnd200484-t001){ref-type="table"}.

###### 

Demographic and clinical baseline characteristics

  MG patients N = 99       
  ------------------------ -----------
  Age, y                    57.4±18.1
  Age at onset, y           45.5±20.0
  Gender                   
    Male                     34 (34)
    Female                   65 (66)
  Antibodies               
    AChR+                    71 (72)
    MuSK+                     8 (8)
    Seronegative             20 (20)
  Phenotype                
    Oculobulbar              24 (24)
    Generalized              75 (76)
  Thymectomy               
    Yes, with thymoma         8 (8)
    Yes, without thymoma      7 (7)
    No                       84 (85)
  QMG                        6.7±4.8
  QMG*ob*                    2.2±2.5
  QMG*gen*                   4.4±3.7
  MG-ADL                     4.8±3.5
  MG-ADL*ob*                 3.1±2.6
  MG-ADL*gen*                1.8±1.7
  MGII                      19.5±15.0
  MGII*ob*                  12.0±10.6
  MGII*gen*                  7.5±7.1
  MGC                        7.0±6.5
  EQ VAS                    67.7±19.4
  ACTIVLIM                   3.6±2.1

Baseline characteristics of 99 patients with MG included in this study. Data are presented as number of patients (%) for categorical variables and as mean±SD for continuous variables.

Cross-cultural translation {#sec0040}
--------------------------

In the back translated version of the MGII, only the item assessing leg weakness with effort was different. The original item is phrased as weakness after walking a certain number of blocks. In the Netherlands, blocks are not commonly used, so blocks were converted to meters, and we kept this wording as it is culturally appropriate. All other items are a literal translation of the original.

Construct validity {#sec0045}
------------------

The mean total MGII score was 19.5±15.0, the mean oculobulbar score 12.0±10.6, and the mean generalized subscore 7.5±7.1. MGII had a lower floor effect (4%) compared to QMG (6%), MG-ADL (11%) and MGC (16%). Generalized MG patients (N = 75) had a significantly higher MGIIgen than oculobulbar MG patients (N = 24) (8.6±6.9 and 4.3±6.7; *p* = 0.01, respectively). There were non-significant differences between generalized and oculobulbar MG patients when comparing QMGgen (4.7±3.9 and 3.6±2.9; *p* = 0.14, respectively) and MG-ADLgen (1.7±1.6 and 2.2±2.0; *p* = 0.25, respectively). [Table 2](#jnd-7-jnd200484-t002){ref-type="table"} shows the correlations between MGII and other outcome measures.

###### 

Correlation between MGII and other measures

  Comparison measure         Pearson r (95% CI)        *p* Value
  -------------------- ------------------------------ -----------
  QMG                       0.68 (0.56 to 0.77)         \<0.001
  MG-ADL                    0.83 (0.76 to 0.88)         \<0.001
  MGC                       0.74 (0.64 to 0.82)         \<0.001
  EQ VAS                -- 0.57 (-- 0.69 to -- 0.42)    \<0.001
  ACTIVLIM              -- 0.48 (-- 0.62 to -- 0.31)    \<0.001

Correlations between MGII and other outcome measures are shown. With these correlations construct validity was tested. In ACTIVLIM and EQ VAS higher scores indicate a higher activity level or quality of life.

Responsiveness to change in generalized muscle weakness {#sec0050}
-------------------------------------------------------

The correlations between *Δ*MGIIgen and *Δ*QMGgen or between *Δ*MG-ADLgen and *Δ*QMGgen were both significant (B = 0.78, *p* \< 0.001, and B = 1.50, *p* = 0.01, respectively). The MGIIgen score has a range of 0-- 31, whereas the MG-ADLgen has a range of 0-- 9, which explains why *Δ*MGIIgen has a more significant correlation compared to *Δ*MG-ADLgen notwithstanding the lower B coefficient. The mean deviation of *Δ*MG-ADLgen from the predicted values of *Δ*QMGgen was 3.5±2.5. *Δ*MGIIgen had an additional value on top of *Δ*MG-ADLgen in the prediction of QMGgen (B = 0.54, *p* = 0.01; [Fig. 1](#jnd-7-jnd200484-g001){ref-type="fig"}).

![Analysis of the additional sensitivity of *Δ*MGII*gen* on top of *Δ*MG-ADL*gen* for *Δ*QMG*gen* in 10 patients with two visits. The dots show the *Δ*QMG*gen* residual for each individual patient. The *Δ*QMG*gen* residual is the difference between observed and predicted *Δ*QMG*gen* based on the *Δ*MG-ADL score of that patient. The B coefficient (slope) shows the degree in which *Δ*MGII correlates with the residual of *Δ*QMG*gen*. The significant correlation implies that *Δ*MGII can to some degree compensate for the mismatch between observed and predicted *Δ*QMG*gen* and therefore has an additional sensitivity for generalized muscle weakness on top of *Δ*MG-ADL.](jnd-7-jnd200484-g001){#jnd-7-jnd200484-g001}

DISCUSSION {#sec0055}
==========

The MGII scale was cross-culturally validated in a cohort of 99 Dutch MG patients. *Δ*MGIIgen had a significantly higher sensitivity for changes in generalized weakness than *Δ*MG-ADLgen. Similarly to the findings of Barnet et al., the MGIIgen subscore was significantly higher in generalized patients compared to oculobulbar patients. In contrast, MG-ADLgen was not capable of differentiating oculobulbar from generalized patients.

The correlation of MGII to both other MG-specific measures and non-specific measures were all within the range (r = 0.6--0.8 and r = 0.4--0.7, respectively) as hypothesized by the developers of the MGII. Only the MG-ADL was slightly above the hypothesized range (0.83), which also was the case in the previous study of Barnett et al. The floor effects found in this study and in that of Barnett et al. were (almost) identical for MGII (4% and 5%, respectively) and for MGC (16% in both studies). The floor effect of MG-ADL found in our study was lower (11%) than that found in the study of Barnet et al. (22%). Nonetheless, the floor effect of MGII was shown to be clearly lower than that of MG-ADL.

Limitations of this study include the single center of inclusion and our study population within a tertiary referral center that may not fully reflect the total MG population due to a referral bias. Moreover, it might be argued that QMGgen is not a 'gold standard' regarding changes in objective generalized muscle weakness. In this study, we chose to use QMGgen as reference for generalized weakness as the QMG score is the best-known structured way of quantifying muscle weakness in MG and has a high focus on generalized weakness (8 out of 13 items).

Weakness in MG is not 'unidimensional' and muscle groups do not respond equally to different therapies. Outcome measures should therefore be sensitive to changes in both oculobulbar and generalized weakness. This study has shown that in addition to the high construct validity of the MGII in general, this outcome measure is more sensitive to changes in generalized weakness than the MG-ADL. We recommend including MGII in future clinical trials.
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